Altamira Therapeutics (FRA:2QA) Total Assets: €6.18 Mil (As of Jun. 2025)


FRA:2QA Altamira Therapeutics Ltd FRA:2QA
30 GF Score
Price €948.00
! 4 Warning Signs
View Full Analysis

What is Altamira Therapeutics Total Assets?

Altamira Therapeutics FRA:2QA 30 Total Assets is €6.18 Mil as of Jun. 2025. GuruFocus rates FRA:2QA with a GF Score™ of 30/100. The stock has 4 warning signs investors should review.

Altamira Therapeutics's Total Assets for the quarter that ended in Jun. 2025 was €6.18 Mil.

During the past 12 months, Altamira Therapeutics's average Total Assets Growth Rate was -11.00% per year. During the past 3 years, the average Total Assets Growth Rate was -27.30% per year. During the past 5 years, the average Total Assets Growth Rate was -5.90% per year. During the past 10 years, the average Total Assets Growth Rate was 16.80% per year.

During the past 13 years, Altamira Therapeutics's highest 3-Year average Total Assets Growth Rate was 64.00%. The lowest was -27.30%. And the median was 20.50%.

Total Assets is connected with ROA %. Altamira Therapeutics's annualized ROA % for the quarter that ended in Jun. 2025 was -36.86%. Total Assets is also linked to Revenue through Asset Turnover. Altamira Therapeutics's Asset Turnover for the quarter that ended in Jun. 2025 was 0.00.

Altamira Therapeutics  (FRA:2QA) Total Assets Explanation

Total Assets is connected with ROA %.

Altamira Therapeutics's annualized ROA % for the quarter that ended in Jun. 2025 is

ROA %=Net Income (Q: Jun. 2025 )/( (Total Assets (Q: Dec. 2024 )+Total Assets (Q: Jun. 2025 ))/ count )
=-2.662/( (8.263+6.182)/ 2 )
=-2.662/7.2225
=-36.86 %

Note: The Net Income data used here is two times the semi-annual (Jun. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Altamira Therapeutics's Asset Turnover for the quarter that ended in Jun. 2025 is

Asset Turnover
=Revenue (Q: Jun. 2025 )/( (Total Assets (Q: Dec. 2024 )+Total Assets (Q: Jun. 2025 ))/ count )
=0/( (8.263+6.182)/ 2 )
=0/7.2225
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Altamira Therapeutics Total Assets Related Terms

Altamira Therapeutics Total Assets Historical Data

* Premium members only.

The historical data trend for Altamira Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Altamira Therapeutics Total Assets Chart

Altamira Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.57 18.56 6.43 8.39 8.26

Altamira Therapeutics Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.37 8.39 7.50 8.26 6.18
FRA:2QA
30GF Score
Altamira Therapeutics Ltd FRA:2QA
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Altamira Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Altamira Therapeutics's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Assets=Total Equity (A: Dec. 2024 )+Total Liabilities (A: Dec. 2024 )
=6.27+1.993
=8.26

Altamira Therapeutics's Total Assets for the quarter that ended in Jun. 2025 is calculated as

Total Assets=Total Equity (Q: Jun. 2025 )+Total Liabilities (Q: Jun. 2025 )
=3.532+2.65
=6.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of €6.18 Mil mean?
Altamira Therapeutics (FRA:2QA) has a Total Assets of €6.18 Mil as of Jun. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Altamira Therapeutics and its competitors.
Is Altamira Therapeutics' Total Assets too high?
Altamira Therapeutics' current Total Assets is €6.18 Mil. Overall, Altamira Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Altamira Therapeutics' Total Assets compare to IOBTQ and SCPX?
Altamira Therapeutics' Total Assets of €6.18 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Altamira Therapeutics and its competitors. Altamira Therapeutics's current Total Assets is €6.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Altamira Therapeutics stock overvalued right now?
Altamira Therapeutics (FRA:2QA) has a current Total Assets of €6.18 Mil. The current Total Assets is €6.18 Mil. Altamira Therapeutics' overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Altamira Therapeutics (FRA:2QA), the current Total Assets is €6.18 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Altamira Therapeutics Business Description

Other Exchanges CYTOF:USA
Address 2 Church Street, Clarendon House, Hamilton, BMU, HM11
Altamira Therapeutics Ltd is developing and supplying peptide-based nanoparticles for safe and effective RNA delivery to extrahepatic tissues (xPhore platform). The Company is offering biopharmaceutical companies access to its technology for use with their own RNA molecules under collaboration and licensing agreements. The xPhore platform is suitable for various RNA modalities - OligoPhore for oligonucleotides, SemaPhore for mRNA, CycloPhore for circRNA - as well as for DNA (GenePhore). In addition, Altamira Therapeutics is pursuing two proprietary flagship development programs using OligoPhore: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. Geographically, the companies operates in United Staes and Switzerland.
30GF Score

Get the complete analysis for FRA:2QA

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€948.00
Price